Everett Moding, MD, PhD @everettmoding

#PhysicianScientist @StanfordRadOnc studying #radiationbiology and #cancerevolution using #ctDNA and #GEMMs modinglab.stanford.edu Stanford, CA Joined December 2010

Tweets

403
Followers

800
Following

757
Likes

846

Everett Moding, MD, PhD @everettmoding

2 weeks ago

@philippewilli @JCO_ASCO We only monitored SNVs in this study, and ctDNA cleared after resection in all patients with dedifferentiated liposarcoma.

0 0 1 24 0

View Details

Everett Moding, MD, PhD @everettmoding

2 months ago

Soft tissue sarcomas (#STS) have few recurrent mutations, making ctDNA testing a challenge. In our new paper in @JCO_ASCO, we show that personalized ctDNA analysis achieves high detection rates and can track treatment response in localized STS. 🧵 (1/11) doi.org/10.1200/JCO-26…

5 10 38 5K 7

View Details

Anthony T. Nguyen, MD, PhD @AnthonyNguyenMD

2 weeks ago

2nd Annual @RRS_RadRes-@sitcancer Joint Session drew a standing room crowd! Spoke on "Immunological Modulation by Radiation" w/ @everettmoding on the dual, context-dependent role of inflammatory TME in sarcoma vs TNBC/prostate. Thx to @DemariaLab_WCM & @HenningWillers for invite.

2 4 8 761 0

View Details

Everett Moding, MD, PhD @everettmoding

2 weeks ago

@philippewilli @JCO_ASCO We detected ctDNA pre-treatment in 4 out of 5 patients with dedifferentiated liposarcoma (80%). The numbers are small, but this is similar to the full cohort.

1 0 0 26 0

View Details

Stand Up To Cancer @SU2C

3 weeks ago

Several years ago, Rob Preece, a long-time marathon runner, developed a soreness in his leg that wasn’t going away. Eventually, a lump appeared in the same spot. A biopsy revealed something he never could have expected: a rare and aggressive form of sarcoma called UPS. Rob’s doctor, @AngelaHong of @Sydney_Uni, told him about a clinical trial supported by #StandUpToCancer and led by @DrDavidKirsch and @EverettModing that was testing a new treatment approach for UPS. Rob enrolled in the trial and now, more than 2 years later, he is cancer-free and enjoying life, including frequent outings with his granddaughter to get ice cream. “This trial was life saving for me.” ❤️ The results of this SU2C-funded clinical trial represented the first significant improvement in the treatment of this form of sarcoma in decades. Learn more about Rob’s story and this cancer research breakthrough at SU2C.link/SarcomaBreakth….

0 7 19 3K 0

View Details

Henning Willers, MD, FASTRO @HenningWillers

3 weeks ago

Grateful for 2nd Joint @sitcancer & @RRS_RadRes Symposium at #RadRes2026 on radiation/immunology topics, how radiation shapes the anti-tunor response☢️ Inspiring correlative science talks from @everettmoding & @AnthonyNguyenMD + 3 oral abstract talks🙏🙏🙏 Looking forward to more collaborations between our Societies 👍

3 7 19 2K 0

View Details

Marina Francis, PhD @marinafrancis7

4 weeks ago

Despite the Nor'Easter crashing #ASTRO26's party, it's a pleasure to make it to the comprehensive #RadOnc annual meeting for the 3rd year in a row, and present my work in the Moding Lab! P.S. I hope the organizing team considers #SanDiego for upcoming meetings ☀️😅

0 1 11 333 0

View Details

Journal of Clinical Oncology @JCO_ASCO

a month ago

Now out in #JCO 👇 Personalized Circulating Tumor DNA Analysis for Predicting Outcomes and Tracking Response to Radiotherapy and Pembrolizumab in Localized Sarcomas: Analysis of the SU2C-SARC032 Trial. Co-authored by @everettmoding. Read the article: bit.ly/4xGXj9C

0 9 26 3K 4

View Details

Stanford Radiation Oncology @StanfordRadOnc

a month ago

Please join us in congratulating @everettmoding, MD, PhD, for receiving the @RRS_RadRes Scholar-in-Training Excellence in Mentorship award! This award honors an individual who has provided exceptional mentoring to a Scholar-in-Training member. Congratulations!

0 4 14 649 0

View Details

Journal of Clinical Oncology @JCO_ASCO

a month ago

Personalized Circulating Tumor DNA Analysis for Predicting Outcomes and Tracking Response to Radiotherapy and Pembrolizumab in Localized Sarcomas: Analysis of the SU2C-SARC032 Trial. Co-authored by @everettmoding. Read the full article. bit.ly/4xJCsDf

2 3 14 3K 8

View Details

Everett Moding, MD, PhD @everettmoding

2 months ago

@SprakerMDPhD I think so!

0 0 2 68 0

View Details

Everett Moding, MD, PhD @everettmoding

2 months ago

@aadel_chaudhuri @JCO_ASCO Thank you, @aadel_chaudhuri!

0 0 1 86 0

View Details

Everett Moding, MD, PhD @everettmoding

2 months ago

Thank you to @SARCtrials for sponsoring and conducting this trial at 20 sites around the world. This work was supported by a @SU2C Catalyst Grant with support from @Merck, @theNCI, and the DoD. Finally, we are grateful to patients and their caregivers for participating. (11/11)

0 0 3 102 0

View Details

Everett Moding, MD, PhD @everettmoding

2 months ago

Grateful to @DKirschMDPhD, @YvonneMowery, @richardriedelmd, and Brian Brigman for leading a hugely impactful trial with rich correlative samples. Thank you to all our co-authors for making this possible! @ShaghayeghSoudi, @SiyerRoohani, @AngelaHong, @MattRijn (10/11)